adiofrequency ablation is an effective treatment strategy for ischemic and nonischemic cardiomyopathy-related ventricular tachycardia (VT). The role of substrate-guided ablation, performed using electrogram characteristics (low amplitude, fractionated or isolated potentials) as scar surrogates, is expanding because of frequent hemodynamic instability during entrainment mapping of scarrelated VT. Late gadolinium-enhancement on cardiac magnetic resonance imaging (LGE-MRI) can accurately characterize the transmural extent, location, and configuration of ventricular scar.
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adiofrequency ablation is an effective treatment strategy for ischemic and nonischemic cardiomyopathy-related ventricular tachycardia (VT). The role of substrate-guided ablation, performed using electrogram characteristics (low amplitude, fractionated or isolated potentials) as scar surrogates, is expanding because of frequent hemodynamic instability during entrainment mapping of scarrelated VT. Late gadolinium-enhancement on cardiac magnetic resonance imaging (LGE-MRI) can accurately characterize the transmural extent, location, and configuration of ventricular scar. 1 Integration of LGE-MRI into electroanatomical mapping during VT ablation was shown, in preliminary studies, to be feasible and to provide accurate localization of VT substrate and reentry circuits. [2] [3] [4] However, studies to date examining the impact of MRI scar integration on procedural outcomes have lacked control groups, precluding any comparisons with standard practice. We performed a study to (1) demonstrate the feasibility in clinical practice of integrating MRI-derived scar for guidance of VT ablation; (2) report on the periprocedural performance of LGE-MRI in identifying the arrhythmogenic substrate; and (3) examine the impact of MRI-guided ablation on procedural length and acute and long-term outcomes.
STUDY DESIGN
In this prospective multicenter study, we enrolled 24 consecutive patients with ischemic (n=9) and nonischemic cardiomyopathy (n=15), referred for catheter ablation of scar-related monomorphic VT. Patients were assigned, at the discretion of the treating physician (not randomized), to undergo either MRI-derived scarguided ablation or traditional ablation. Clinical characteristics of patients in both groups were statistically comparable with a higher tendency to use scar integration for patients with prior failed ablation, lower left ventricular ejection fraction, and epicardial circuits (Table I in the Data Supplement).
MRI acquisition and analysis, as well as standard ablation strategy, are fully described in the supplement. Briefly, an electrophysiology study, using programmed stimulation, was performed at the procedure onset to induce the clinical VT(s) and to enable the identification and ablation of VT critical sites by pace mapping or entrainment mapping. Additional ablation targets included areas with fractionated, isolated, and low-voltage potentials. In MRI scar-guided ablation, registration of LGE map and electroanatomical mapping was accomplished, and regions exhibiting LGE were carefully interrogated to identify low-voltage or abnormal electrograms. Entrainment mapping or pace mapping maneuvers were then performed in regions with LGE to ascertain their involvement in clinical VT. LGE areas were ablated if found to be implicated in VT, and areas with LGE and abnormal electrograms were ablated in a substrate modification strat- Patients were followed post-procedure with regular implantable cardioverter defibrillator interrogations, Holter monitoring, or ECG recordings. The primary end point was long-term freedom from target VT recurrence. Table I and Figure II in the Data Supplement exhibit procedural and MRI scar data, respectively. In the scar integration group, all patients with inducible VTs had evidence of LGE on MRI, and ablation within or at the border of LGE sites terminated the arrhythmia in all these patients (100% match between clinical VT critical sites and LGE). In patients without LGE on MRI, sustained VT could not be induced. In 1 patient with nonischemic cardiomyopathy, MRI revealed LGE in the midinferior wall, correlating with low-voltage and abnormal potentials on electroanatomical mapping. In this patient, VT could not be elicited on various maneuvers, and substrate modification was done using radiofrequency energy in that area. Data on interrogation of LGE areas for abnormal electrograms were available in 9 of 13 patients in scar merge group. Abnormal electrograms were colocalized with LGE in all patients and were targeted by ablation in patients in whom a substrate modification approach was adopted. Procedural, fluoroscopy, and ablation times, as well as ablation burden, were similar in both study arms (P>0.05). Acute procedural success (clinical VT termination or noninducibility) was achieved in all patients.
RESULTS
During a median follow-up of 38.5 interquartile range (26-53) months, 16 (73%) patients had VT recurrence (7 in the study group versus 9 controls; Table II in the Data Supplement). After adjusting for age, sex, cardiac substrate, epicardial ablation, and left ventricular ejection fraction, MRI-guided ablation was associated with reduced VT recurrence during follow-up (hazard ratio, 0.12; 95% confidence interval, 0.02-0.75; P=0.023). Follow-up echocardiographic studies were performed in a subset of patients and described in the Data Supplement.
DISCUSSION
The current study is the first to evaluate the impact of integration of LGE-MRI scar into electroanatomical mapping during VT ablation on long-term procedural outcome using a control group for comparison. The main findings of this study are as follows: (1) integration of MRI-derived scar during VT ablation is feasible; (2) MRI-defined scar accurately identifies VT substrate without differences on procedural or fluoroscopy time; (3) acute ablation success rates were similar in procedures performed with and without scar merging; and (4) after adjusting for clinical parameters, MRI-guided ablation was associated with decreased risk of longterm VT recurrence.
Incorporation of the LGE-derived scar facilitates VT ablation in the setting of hemodynamic instability that precludes conventional electrophysiological mapping and dense point-by-point voltage mapping and may shorten procedure time devoted to substrate identification.
LGE-MRI can also complement VT substrate mapping by focusing substrate mapping on scar regions. Indeed, regional necrosis/fibrosis is accompanied by hypertrophy of adjacent viable tissue (as a result of remodeling), 5 exhibit normal voltage, and be glossed over after identification of sparse neighboring healthy points. Mid-wall scar may also contain critical parts of VT reentry circuits and, while missed on bipolar voltage mapping, can be displayed on integration of MRI scar. We think that scar integration enhances the operator's ability to target substrate that would otherwise have been missed, potentially improving patient outcomes. In addition, MRI scar integration may impact safety by avoiding unnecessary ablation of healthy myocardium in procedures guided solely by voltage mapping. In fact, false-positive low-voltage may be because of poor contact, thinner walls, or epicardial fat, leading to overestimation of arrhythmogenic substrate. Study limitations are listed in the Data Supplement. 
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